This is certainly an interesting read if you want to gain a little perspective concerning how much revenue and profit is being made on PwMS by just one drug business:

http://newsroom.biogen.com/press-releas ... 30-billion

The MS drug revenues pull in the lion's share of the staggering $3 billion for the quarter. So our misfortune translates to at least a good $10 billion per year cash machine that is growing like a wildfire. With the flow of cash like this, one has to be mindful that anyone who benefits from the cash spinoff of enterprises like this--investors, company executives, doctors and healthcare professionals, scientists and researchers, etc., etc. would not have much motivation to develop a cure or an effective, non-toxic treatment program.